Patents and litigation

A US patent victory could give Amgen’s Enbrel another eight years’ patent exclusivity, but is the enthusiasm justified?

The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.

April 11, 2017

The US regulator has come down surprisingly hard on biotech stock promotion schemes.

April 03, 2017

Acorda and Forward have been bashed by unfavourable US patent verdicts in multiple sclerosis, while Steadymed got a boost.

Latest Reports